ClinicalTrials.gg
RecruitingNCT07129343Updated Jan 8, 2026

A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)

A Phase 3 interventional study of VONVENDI and ADVATE in Von Willebrand Disease (VWD), sponsored by Takeda. Recruiting at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in von Willebrand Diseases by Takeda — 3 open to participants now, 3 under way, 2 of them phase 3. von Willebrand Diseases · Takeda.

Started
2025
the only one that year
Phase 3
7 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in von Willebrand Diseases by Takeda, this one is the only one that started in 2025, is one of 7 in phase 3, and was the 12th registered.

von Willebrand Diseases

96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.

Browse von Willebrand Diseases studies →

Open to participants now

3 of the 13 studies in von Willebrand Diseases by Takeda are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 23 von Willebrand Diseases studies recruiting now, 15 (65%) set no upper age limit and 8 (35%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in von Willebrand Diseases by Takeda, or all of them as a file.
02

Study summary

The main aim of this study is to find out if VONVENDI is safe for adult Chinese participants with VWD. The study will also check how well VONVENDI helps control bleeding with or without product ADVATE in the participants who may need elective surgery or dental procedures. In addition, the study will also examine how VONVENDI is processed by the body (known as pharmacokinetic [PK]) and how the drug helps the body respond or improve a condition (pharmacodynamic [PD]).

Participants will receive an initial dose of VONVENDI of 40 to 80 international units per kilogram (IU/kg) of body weight. If a participant's baseline factor VIII (FVIII) level is not high enough to help stop bleeding, VONVENDI will be given along with 30 to 45 IU/kg of ADVATE rFVIII.

Participants will be in the study for approximately 14 months. During the study, participants will be followed up at clinics or over telephone calls.

03

Conditions studied

  • Von Willebrand Disease (VWD)

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must voluntarily sign an institutional review board (IRB)/independent ethics committee-approved written form after all relevant aspects of the study have been explained and discussed with the participant.
  2. Participant has a documented diagnosis of severe VWD (baseline VWF:RCo less than [\<]20 international units [IU]deciliter [dL]) with a diagnosis of VWD type verified per the following recommended criteria:

    • Type 1 (von Willebrand factor:Ristocetin cofactor activity [VWF:RCo] \<20 IU/dL and by VWF activity/VWF:antigen [Ag] ratio) or,
    • Type 2A or type 2B (by VWF activity/VWF:Ag ratio and multimer pattern, with genetics if necessary), type 2N (FVIII:C \<10% and genetics), type 2M (by VWF activity/VWF:Ag ratio and multimer pattern) or
    • Type 3 (VWF:Ag \<=3 IU/dL). Diagnosis is confirmed, when applicable, by genetic testing and/or by multimer analysis.
  3. Participant is at least 18 years of age at screening.
  4. Participant is ethnic Chinese and lives in China, including those from Taiwan, Hong Kong, and Macao.
  5. If female of , participant presents with a negative pregnancy test and agrees to employ adequate measures for the duration of the study.
  6. Participant is willing and able to comply with the requirements of the protocol.
  7. Participant has had a minimum of 3 documented bleeds that indicated the need for VWF coagulation factor replacement therapies during the previous 12 months prior to enrollment.

Exclusion criteria

Exclusion Criteria

  1. Participant has been diagnosed with pseudo VWD or another hereditary or acquired coagulation disorder other than VWD (example [eg], qualitative and quantitative disorders or elevated [PT]/international normalized ratio >1.4).
  2. Participant has a history or presence of a VWF inhibitor at screening.
  3. Participant has a documented history of a VWF:RCo half-life of \<6 hours.
  4. Participant has a history or presence of a FVIII inhibitor with a titer greater than or equal to [>=] 0.6 Bethesda units per milliliter [BU/mL] (by Bethesda assay or Bethesda method with Nijmegen modification).
  5. Participant has a known to any of the components of the study drugs, such as to mouse or hamster proteins.
  6. Participant has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, mild asthma, food allergies or animal allergies.
  7. Participant has a medical history of a thromboembolic event.
  8. Participant is (HIV) positive with an absolute cluster of differentiation 4 (CD4) count \<200/cubic millimeter (mm\^3).
  9. Participant has been treated with an immunomodulatory drug, other than antiretroviral chemotherapy eg, α-interferon, or agents at a dose equivalent to hydrocortisone greater than 10 milligram (mg)/day (excluding topical treatment [eg, ointments, nasal sprays]), within 30 days prior to signing the (or assent, if appropriate).
  10. Participant is pregnant or lactating at the time informed consent is obtained.
  11. Participant has participated in another clinical study involving an IP, or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
  12. Participant is diagnosed with progressive fatal disease and/or has a of less than 15 months.
  13. Participant is member of the study team conducting this study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (that is, children, partner/spouse, siblings, parents) as well as employees.
  14. Participant has an acute illness (eg, influenza, flu-like syndrome, allergic rhinitis/conjunctivitis, nonseasonal asthma) at screening.
  15. Participant is diagnosed with significant liver disease, as evidenced by, but not limited to, any of the following: serum (ALT) greater than 5 times the ; hypoalbuminemia; portal vein hypertension (eg, presence of otherwise unexplained splenomegaly, history of esophageal varices) or liver cirrhosis classified as class B or C.
  16. Participant has been diagnosed with renal disease, with a serum creatinine level >=2.5 milligram per deciliter (mg/dL).
  17. Participant has a platelet count \<100,000/ milliliter (mL) at screening (except for participants with type 2B VWD, whose platelet count[s] at screening will be evaluated taking into consideration historical trends in platelet counts and the investigator's medical assessment of the participant's condition).
  18. Participant has cervical or uterine conditions causing menorrhagia or metrorrhagia (including infection, dysplasia).
  19. In the judgment of the investigator, the participant has another concomitant condition (eg, uncontrolled hypertension) that may pose additional risks for the participant.
  20. Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    All Participants With VWD

    Participants will receive a single intravenous (IV) dose of VONVENDI at baseline PK assessment. During the 12-month on-demand (OD) treatment period, any bleeding episodes requiring replacement therapy with VWF will be treated with VONVENDI with or without ADVATE. Participants may also receive VONVENDI with or without ADVATE intravenous infusions, when indicated deemed necessary for perioperative bleeding management \[major, minor and oral surgery\]. Participants will receive initial dose of VONVENDI of 40 to 80 IU/kg of body weight.

    Biological: VONVENDI · Biological: ADVATE

Interventions

  • BiologicalVONVENDI

    VONVENDI is administered by intravenous injection.

    Also known as: vonicog alfa, TAK-577, rVWF

  • BiologicalADVATE

    ADVATE is administered by intravenous injection.

    Also known as: rFVIII, Octocog alfa

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. An SAE is any untoward medical occurrence that at any dose: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event in the opinion of the healthcare provider, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. TEAEs consist of both serious and non-serious adverse events.

    Time frame: Up to 14 months

  2. Number of Participants With TEAEs by Severity

    Number of participants with severity of TEAE will be reported.

    Time frame: Up to 14 months

  3. Number of Participants With TEAEs and SAEs by Causality

    Number of participants with causality related TEAEs and SAEs will be reported.

    Time frame: Up to 14 months

  4. Number of Participants With Thromboembolic Events and Severe Hypersensitivity Reactions

    Number of participants with thromboembolic events and severe hypersensitivity reactions will be reported.

    Time frame: Up to 14 months

  5. Number of Participants Who Develop Neutralizing (Inhibitory) Antibodies to VWF and FVIII

    Number of participants who develop neutralizing antibodies to VWF and FVIII will be reported.

    Time frame: Up to 14 months

  6. Number of Participants Who Develop Binding Antibodies to VWF and FVIII

    Number of participants who develop total binding antibodies to VWF and FVIII will be reported.

    Time frame: Up to 14 months

  7. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Number of participants with clinically significant abnormalities from baseline values in laboratory parameters per investigator assessment will be reported.

    Time frame: Up to 14 months

  8. Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG)

    Number of participants with clinically significant abnormalities from baseline values in ECG per investigator assessment will be reported.

    Time frame: Up to 14 months

  9. Number of Participants With Clinically Significant Abnormalities in Vital Signs Parameters

    Number of participants with clinically significant abnormalities from baseline values in vital sign parameters per investigator assessment will be reported.

    Time frame: Up to 14 months

Secondary outcomes

  1. Number of Infusions of VONVENDI With or Without ADVATE per Bleeding Episode

    Number of infusions of VONVENDI with or without ADVATE per bleeding episode will be reported.

    Time frame: Up to 12 months

  2. Number of Infusions of ADVATE per Bleeding Episode

    Number of infusions of ADVATE per bleeding episode will be reported.

    Time frame: Up to 12 months

  3. Weight-adjusted Consumption of VONVENDI and ADVATE per Bleeding Episode

    Weight-adjusted consumption of VONVENDI and ADVATE per bleeding episode will be reported.

    Time frame: Up to 12 months

  4. Time to Resolution of Bleeding Episodes

    Time to resolution of the bleeding episodes will be calculated as the difference between the date/time of the first IP infusion for the bleeding episode to the date/time of the bleeding episode resolution.

    Time frame: Up to 12 months

  5. Area Under the Plasma Concentration/Time Curve From Time 0 to Infinity (AUC0-inf) for VWF: Ristocetin Cofactor (VWF:Rco), VWF: Antigen (VWF:Ag) and VWF: Collagen Binding Capacity (VWF:CB)

    AUC0-inf parameter at the baseline PK assessment will be calculated using noncompartmental analysis (NCA) for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  6. Dose Normalized AUC (0-inf) for VWF:RCo, VWF:Ag and VWF:CB

    Dose normalized AUC0-inf parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  7. AUC From Time 0 to 96 Hours (AUC0-96h) for VWF:RCo, VWF:Ag and VWF:CB

    AUC0-96h parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  8. Dose Normalized AUC(0-96h) for VWF:RCo, VWF:Ag and VWF:CB

    Dose normalized AUC0-96h parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  9. Maximum Plasma Concentration (Cmax) for VWF:RCo, VWF:Ag and VWF:CB

    Cmax parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  10. Dose Normalized Cmax for VWF:RCo, VWF:Ag and VWF:CB

    Dose normalized Cmax parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  11. Time to Reach Maximum Plasma Concentration (Tmax) for VWF:RCo, VWF:Ag and VWF:CB

    Tmax parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  12. Mean Residence Time for VWF:RCo, VWF:Ag and VWF:CB

    Mean residence time parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  13. Clearance for VWF:RCo, VWF:Ag and VWF:CB

    Clearance parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  14. Terminal Half-life (T1/2) for VWF:RCo, VWF:Ag and VWF:CB

    T1/2 parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  15. Volume of Distribution at Steady State (Vss) for VWF:RCo, VWF:Ag and VWF:CB

    Vss parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo, VWF:Ag, and VWF:CB.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  16. Incremental Recovery (IR) at Cmax for VWF:RCo and VWF:Ag

    IR parameter at the baseline PK assessment will be calculated using NCA for VWF:RCo and VWF:Ag.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  17. AUC From Time 0 to Last time of Measurable Activity (AUC0-tlast) for Factor VIII:Coagulation Activity (FVIII:C)

    AUC0-tlast parameter at the baseline PK assessment will be calculated using NCA for FVIII: C.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  18. Dose Normalized AUC0-tlast for FVIII:C

    Dose Normalized AUC0-tlast parameter at the baseline PK assessment will be calculated using NCA for FVIII: C.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  19. AUC0-96h for FVIII:C

    AUC0-96h parameter at the baseline PK assessment will be calculated using NCA for FVIII: C.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  20. Dose Normalized AUC0-96h for FVIII:C

    Dose normalized AUC0-96h parameter at the baseline PK assessment will be calculated using NCA for FVIII: C.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  21. Cmax for FVIII:C

    Cmax parameter at the baseline PK assessment will be calculated using NCA for FVIII: C.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  22. Dose Normalized Cmax for FVIII:C

    Dose Normalized Cmax parameter at the baseline PK assessment will be calculated using NCA for FVIII: C.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  23. Tmax for FVIII:C

    Tmax parameter at the baseline PK assessment will be calculated using NCA for FVIII: C.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  24. Plasma Level of VONVENDI based on Von Willebrand Factor: Ristocetin Cofactor (VWF:Rco)

    Plasma level of VONVENDI based on VWF:Rco will be reported.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  25. Plasma Level of VONVENDI based on Von Willebrand Factor Antigen (VWF:Ag)

    Plasma level of VONVENDI based on VWF:Ag will be reported.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  26. Plasma Level of VONVENDI based on Von Willebrand Factor Collagen Binding (VWF:CB)

    Plasma level of VONVENDI based on VWF:CB will be reported.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  27. Plasma Level of Factor VIII Clotting (FVIII:C)

    Plasma level of FVIII:C will be reported.

    Time frame: At baseline: Within 1 hour pre-infusion, 0.25, 0.50, 1, 3, 6, 12, 24, 30, 48, 72, and 96 hours post-infusion

  28. Total Hemostatic Efficacy Assessment 24 hours After Last Perioperative IP Infusion or at Day 14 Postoperative Visit

    The overall hemostatic efficacy of VONVENDI, with or without ADVATE, will be assessed by the investigator using the hemostatic efficacy assessment rating scale either 24 hours after the last perioperative infusion or at the Day 14 postoperative visit, whichever comes first.

    Time frame: At 24 hours or Day 14

  29. Total Volume of Actual and Predicted Intraoperative Blood Loss After the Surgery as Assessed by the Operating Surgeon

    Intraoperative actual blood loss will be assessed by the operating surgeon at the completion of surgery using a predefined 4-point rating scale. 1- Excellent (intraoperative blood loss was less than or equal to the maximum expected for the type of procedure performed in a hemostatically normal individual \[\<=\]100 percent \[%\]); 2- Good (intraoperative blood loss up to 50% more than the maximum expected blood loss for the type of procedure performed in a hemostatically normal individual \[101%-150%\]); 3- Moderate (intraoperative blood loss exceeding 50% of the expected for the type of procedure performed in a hemostatically normal individual \[greater than (\>)150%\]); 4- None (uncontrolled hemorrhage due to an inadequate therapeutic response despite appropriate dosing, necessitating a change of clotting factor replacement regimen). Lower scores indicate better hemostatic efficacy. Scoring is calculated by comparing the actual blood loss versus predicted blood loss.

    Time frame: From Intraoperative through completion of surgery (up to Day 14)

  30. Intraoperative Hemostatic Efficacy Score as Assessed by Operating Surgeon at Completion of Surgery

    The hemostasis assessment rating scale ranges from 1 to 4, where 1 = Excellent, 2 = Good, 3 = Moderate, and 4 = None. Lower scores indicate better hemostatic efficacy.

    Time frame: At completion of surgery (up to Day 14)

  31. Daily Intra- and Postoperative Weight-adjusted Dose of VONVENDI With or Without ADVATE Through Postoperative Day 14

    Daily intra- and postoperative weight-adjusted dose of VONVENDI with or without ADVATE through postoperative day 14 will be reported.

    Time frame: From day of surgery through postoperative Day 14

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Nov 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 19, 2025
StartActual
Oct 13, 2025
Primary completionEst.
Nov 25, 2027
CompletionEst.
Nov 25, 2027
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07129343
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Oct 13, 2025
Primary completion
Nov 25, 2027 (estimated)
Completion
Nov 25, 2027 (estimated)
Last update
Jan 8, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vonicog alfa · Antihemophilic factor, human recombinant

Start the discussion